Fan Site: Inspired, Not Endorsed, By Rakesh Jhunjhunwala

Posts tagged Prima Plastics

Eminent Experts Recommend Top-Quality Micro-Cap Stock Which Is “Riding On The Fast Track”



Leading experts have recommended a top-quality micro-cap stock which boasts of high ROE, debt-free status and an excellent management track record. The experts have opined that the stock is “riding on the fast track” and have foreseen that the stock has the potential to give huge gains

Newer Entries →

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 509 other subscribers

RSS Stocks Talk Forum

  • Sunil Singhania's Abakkus has bought 10.69L shares of Aarti Pharma at ₹575 for ₹61.5 Cr
    Sunil Singhania's Abakkus has bought 10.69L shares of Aarti Pharma at ₹575 for ₹61.5 Cr. M-Cap is ₹5800 Cr. Promoters hold 46%. Co operates in 3 areas i.e. Xanthine derivatives, API & CDMO/CMO. It is largest Indian manufacturer of Xanthines & has Global market share of 15-20% ... Sunil Singhania's Abakkus has bought 10.69L shares […]
  • PNB Housing is undergoing a transformation to morph into a franchise that will be stronger
    PNB Housing is undergoing a transformation to morph into a franchise that will be stronger, more resilient & with high predictability in earnings trajectory. Risk-reward profile is favorable for a long-term investor. Buy for TP of ₹1160 (38% upside) Download research... PNB Housing is undergoing a transformation to morph into a franchise that will be […]
  • Piramal Pharma is seeing strong momentum in CDMO. Buy for TP ₹320 (27% upside)
    Piramal Pharma is seeing strong momentum in CDMO. Postponement of the Biosecure Act is unlikely to cause growth related issues as China rebalancing drive by global innovators likely to continue. Other growth levers are intact. Buy for TP ₹320 (27% upside) Download report... Piramal Pharma is seeing strong momentum in CDMO. Buy for TP ₹320 […]
Disclaimer: This is a Fan Site in Rakesh Jhunjhunwala's name. Rakesh Jhunjhunwala is not associated with us and is in no way aware, accountable or responsible for what is stated here. Further, nothing here constiutes investment advice for you to act on. Also, we have a vested interest, and are extremely biased, in everything that we say. So Mind It!